These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9220319)

  • 21. Phase I trial of escalating doses of interleukin-1 beta in combination with a fixed dose of interleukin-2.
    Triozzi PL; Kim JA; Martin EW; Young DC; Benzies T; Villasmil PM
    J Clin Oncol; 1995 Feb; 13(2):482-9. PubMed ID: 7844609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategies to reduce side effects of interleukin-2: evaluation of the antihypotensive agent NG-monomethyl-L-arginine.
    Kilbourn RG; Fonseca GA; Trissel LA; Griffith OW
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S21-30. PubMed ID: 10685654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overview of interleukin-2 inhalation therapy.
    Huland E; Heinzer H; Huland H; Yung R
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S104-12. PubMed ID: 10685669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.
    Sosman JA; Kohler PC; Hank J; Moore KH; Bechhofer R; Storer B; Sondel PM
    J Natl Cancer Inst; 1988 Mar; 80(1):60-3. PubMed ID: 3257526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.
    Pichert G; Jost LM; Fierz W; Stahel RA
    Br J Cancer; 1991 Feb; 63(2):287-92. PubMed ID: 1997108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.
    McDermott DF; Trehu EG; Mier JW; Sorce D; Rand W; Ronayne L; Kappler K; Clancy M; Klempner M; Atkins MB
    Clin Cancer Res; 1998 May; 4(5):1203-13. PubMed ID: 9607578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
    Gollob JA; Sciambi CJ; Peterson BL; Richmond T; Thoreson M; Moran K; Dressman HK; Jelinek J; Issa JP
    Clin Cancer Res; 2006 Aug; 12(15):4619-27. PubMed ID: 16899610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer.
    Kammula US; White DE; Rosenberg SA
    Cancer; 1998 Aug; 83(4):797-805. PubMed ID: 9708948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma.
    Ahmed FY; Leonard GA; A'Hern R; Taylor AE; Lorentzos A; Atkinson H; Moore J; Nicolson MC; Riches PG; Gore ME
    Br J Cancer; 1996 Oct; 74(7):1109-13. PubMed ID: 8855983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study.
    Bauer M; Reaman GH; Hank JA; Cairo MS; Anderson P; Blazar BR; Frierdich S; Sondel PM
    Cancer; 1995 Jun; 75(12):2959-65. PubMed ID: 7773948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma.
    Atkins MB; Redman B; Mier J; Gollob J; Weber J; Sosman J; MacPherson BL; Plasse T
    Clin Cancer Res; 2001 Mar; 7(3):486-92. PubMed ID: 11297238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
    Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
    Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.
    Sosman JA; Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; O'Boyle K; Fisher RI; Boldt DH; Doroshow J
    J Clin Oncol; 1993 Aug; 11(8):1496-505. PubMed ID: 8336188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of interleukin-2 in the biotherapy of cancer.
    Parkinson DR
    Oncol Nurs Forum; 1989; 16(6 Suppl):16-20. PubMed ID: 2687810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer.
    Koretz MJ; Lawson DH; York RM; Graham SD; Murray DR; Gillespie TM; Levitt D; Sell KM
    Arch Surg; 1991 Jul; 126(7):898-903. PubMed ID: 1854252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma.
    Gaynor ER; Weiss GR; Margolin KA; Aronson FR; Sznol M; Demchak P; Grima KM; Fisher RI; Boldt DH; Doroshow JH
    J Natl Cancer Inst; 1990 Sep; 82(17):1397-402. PubMed ID: 2388289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer.
    Webb DE; Austin HA; Belldegrun A; Vaughan E; Linehan WM; Rosenberg SA
    Clin Nephrol; 1988 Sep; 30(3):141-5. PubMed ID: 3263237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.
    Du Bois JS; Trehu EG; Mier JW; Shapiro L; Epstein M; Klempner M; Dinarello C; Kappler K; Ronayne L; Rand W; Atkins MB
    J Clin Oncol; 1997 Mar; 15(3):1052-62. PubMed ID: 9060545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.